Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the ...

Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies.

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...